Trends of consumption and expenditure of antibacterial traditional Chinese medicine in secondary and tertiary hospitals in China: an analysis of pharmaceutical sales data, 2011–2015

doi:10.5246/jcps.2022.04.0275

Abstract

Abstract:

Traditional Chinese medicines (TCMs) are commonly used in China, and some of them have been proved to be effective against infection caused by certain pathogenic bacteria. In the present study, we aimed to describe the trends of antibacterial-effect traditional Chinese medicine (AeTCM) consumption and expenditure in secondary and tertiary hospitals in China using pharmaceutical sales data from January 2011 to December 2015. Aggregated monthly surveillance data on AeTCM sales in China’s hospitals were retrospectively analyzed. Population weighted daily define doses, which are the recommended daily amounts based on dosage regimen recommended in the manufacturers’ instructions, were adopted. The AeTCM consumption was expressed in DDD per 1000 inhabitants per day (DID). The AeTCM expenditure was expressed in US dollars. A compound annual growth rate (CAGR) was used to describe the growth of AeTCM consumption and expenditure. A total of 1293 AeTCMs were matched and analyzed from 468 tertiary hospitals and 114 secondary hospitals from 28 provinces. The total AeTCM consumption and expenditure demonstrated a significant upward trend during the study period from 4.07 DID to 6.82 DID with a CAGR of 13.75%, and 839.75 million US dollars to 1276.82 million US dollars with a CAGR of 11.04%, respectively. Compared with eastern provinces, the consumption of AeTCMs was higher in the central and western provinces. Parenteral AeTCMs accounted for 7.20% of the total AeTCM consumption, but nearly 45% of the total AeTCM expenditure. The AeTCM use in China demonstrated a rapid growth, which could be the result of the substitutional effect from antimicrobial stewardship and brought a potential risk of overuse. More studies are needed to further explore the potential efficacy of AeTCMs as an alternative approach towards infection treatment and to help confine antimicrobial resistance.

Key words: Antibacterial-effect, Traditional Chinese medicine, Drug consumption, Drug expenditure

Supporting:

Yumiti Taxifulati, Yue Zhou, Sheng Han, Kexin Du, Yaoyao Yang, Lin Hu, Bo Zheng, Xiaodong Guan, Haishaerjiang Wushouer, Luwen Shi. Trends of consumption and expenditure of antibacterial traditional Chinese medicine in secondary and tertiary hospitals in China: an analysis of pharmaceutical sales data, 2011–2015[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(4): 298-307.

Figures/Tables 3

References 32

[1]	WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. This article can be found online at https://apps.who.int/iris/bitstream/handle/10665/277359/9789241514880-eng.pdf?ua=1.
[2]	McDonnell, L.; Armstrong, D.; Ashworth, M.; Dregan, A.; Malik, U.; White, P. National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries. J. Antimicrob. Chemother. 2017, 72, 3199–3204.
[3]	Wushouer, H.; Zhang, Z.X.; Wang, J.H.; Ji, P.; Zhu, Q.F.; Aishan, R.; Shi, L.W. Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. J. Infect. Public Heal. 2018, 11, 339–346.
[4]	Xiao, Y.; Li, L. Legislation of clinical antibiotic use in China. Lancet Infect. Dis. 2013, 13, 189–191.
[5]	Xiao, Y.H. Antimicrobial stewardship in China: systems, actions and future strategies. Clin. Infect. Dis. 2018, 67, S135–S141.
[6]	Ji, H.F.; Li, X.J.; Zhang, H.Y. Natural products and drug discovery. EMBO Rep. 2009, 10, 194–200.
[7]	Li, C.Y.; Wang, P.; Zhang, L.; Li, M.; Lei, X.; Liu, S.; Feng, Z.Q.; Yao, Y.M.; Chang, B.; Liu, B.S.; Shang, H.C. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials. J. Ethnopharmacol. 2018, 224, 512–521.
[8]	Fan, X.; Li, N.; Wang, X.; Zhang, J.; Xu, M.; Liu, X.; Wang, B. Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infection. PLoS One. 2018, 13, e0203678.
[9]	Zhang, W.; Wang, B.; Li, Z. Prevention of traditional Chinese medicine Gubiao Pixie prescription for nosocomial infection in elderly population. Chin. Crit. Care Med. 2017, 29, 469–472.
[10]	Ma, Y.X.; Chen, M.; Guo, Y.L.; Liu, J.; Chen, W.T.; Guan, M.Y.; Wang, Y.; Zhao, X.H.; Wang, X.; Li, H.Y.; Meng, L.X.; Wen, Y.L.; Wang, Y.G. Prevention and treatment of infectious diseases by traditional Chinese medicine: a commentary. APMIS. 2019, 127, 372–384.
[11]	Shi, Z.F.; Zhao, C.; Hu, J.Y.; Dai, Q.Q.; Guan, M.K.; Zhong, C.M.; Tian, G.H.; Shang, H.C. The application of traditional Chinese medicine injection on patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. Evid. Based Complement. Altern. Med. 2020, 2020, 3834128.
[12]	Gao, G.Y.; Leung, S.W.; Jia, Y.L. Serious concerns about the RCT study quality of traditional Chinese medicine injections for treating cardiovascular diseases and COVID-19. Cardiovasc. Drugs Ther. 2021, 35, 191–193.
[13]	Tan, L.; Li, M.; Lin, Y. Safety concerns of traditional Chinese medicine injections used in Chinese children. Evid. Based Complement. Altern. Med. 2019, 2019, 8310368.
[14]	Ji, K.M.; Chen, J.J.; Li, M.; Liu, Z.G.; Xia, L.X.; Wang, C.B.; Zhan, Z.K.; Wu, X.L. Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul. Toxicol. Pharmacol. 2009, 55, 134–138.
[15]	Wushouer, H.; Tian, Y.; Guan, X.D.; Han, S.; Shi, L.W. Trends and patterns of antibiotic consumption in China’s tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. PLoS One. 2017, 12, e0190314.
[16]	Lin, H.; Dyar, O.J.; Rosales-Klintz, S.; Zhang, J.Z.; Tomson, G.; Hao, M.; Stålsby Lundborg, C. Trends and patterns of antibiotic consumption in Shanghai municipality, China: a 6 year surveillance with sales records, 2009-14. J. Antimicrob. Chemother. 2016, 71, 1723–1729.
[17]	Chen, J.Y.; Min, R.; Wang, H.; Zhao, S.W.; Li, H.M.; Fang, P.Q. Trends and drivers of inpatient antibiotic consumption among 89 China tertiary general hospitals from 2011Q1 to 2015Q4. Biomed. Res. Int. 2018, 2018, 1–7.
[18]	Wang, Y.; Chao, E.; Wang, G. Guideline for Clinical Application of Chinese Patent Medicine - Infectious Diseases. Beijing: China Press of Traditional Chinese Medicine. 2015.
[19]	National Health and Family Planning Commission of People’s Republic of China. China Health Statistics Yearbook. Beijing: Peking Union Medical College Press. 2012.
[20]	China Statistical Yearbook 2011-2015. This article can be found online at http://www.stats.gov.cn/english/Statisticaldata/AnnualData/.
[21]	WHOCC-ATC/DDD Index. This article can be found online at https://www.whocc.no/atc_ddd_index/.
[22]	The Central Bank of the People’s Republic of China. This article can be found online at http://www.pbc.gov.cn/en/3688006/index.html.
[23]	National Data. This article can be found online at http://data.stats.gov.cn/english/.
[24]	Fujian Provincial Health Commission. Notification on the task of controlling medical expenses in 2011. This article can be found online at http://wjw.fujian.gov.cn/xxgk/zfxxgkzl/zfxxgkml/wszh/zdwssjhd/201105/t20110506_2336896.htm.
[25]	Zhejiang Provincial Health Commission. Guidance on strengthening the control of medical expenses in medical institutions. This article can be found online at http://www.zjwjw.gov.cn/art/2011/12/5/art_1202376_ 3462709.html.
[26]	Cai, Y.; Zhang, Q.; Fu, Y.; Li, L.; Zhao, N.; Lu, A.; Liu, Q.; Jiang, M. Effectiveness of Chinese herbal medicine combined with antibiotics for extensively drug-resistant enterobacteria and nonfermentative bacteria infection: real-life experience in a retrospective cohort. Biomed. Res. Int. 2017, 2017, 2897045.
[27]	Xu, H.R.; Li, M.; Wang, C.X.; Yin, R.Y.; Ma, J.; Wang, M.Z.; Tan, Q.M.; Jiang, L.D.; Cheng, M.; Chen, X.H.; Zhang, L.S.; Su, H.P.; Hao, R.F.; Jiao, Y.; Wang, C.H.; Wei, H.L.; Feng, C.L.; Luo, H.; Zhou, P.G. Evaluation on clinical efficacy of Fuzheng Jiedu Huayu Decoction combined with antibiotics in the treatment of pneumonia in the elderly - A multi-center, double-blind, parallel, randomized controlled trial. Complement. Ther. Med. 2018, 37, 127–132.
[28]	Tsai, C.C.; Lin, C.S.; Hsu, C.R.; Chang, C.M.; Chang, I.W.; Lin, L.W.; Hung, C.H.; Wang, J.L. Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies. BMC Complement. Altern. Med. 2018, 18, 96.
[29]	Chen, X.L.; Shang, F.; Meng, Y.J.; Li, L.; Cui, Y.M.; Zhang, M.; Qi, K.Z.; Xue, T. Ethanol extract of Sanguisorba officinalis L. inhibits biofilm formation of methicillin-resistant Staphylococcus aureus in an Ica-dependent manner. J. Dairy Sci. 2015, 98, 8486–8491.
[30]	Tan, X.J.; Yang, D.T.; Yang, G.X.; Chen, J.H.; Dong, W.; Shi, J.S.; Jia, A.Q. The investigation of inhibiting quorum sensing and methicillin-resistant Staphylococcus aureus biofilm formation from Liriodendron hybrid. Pak. J. Pharm. Sci. 2015, 28, 903–908.
[31]	Kuok, C.F.; Hoi, S.O.; Hoi, C.F.; Chan, C.H.; Fong, I.H.; Ngok, C.K.; Meng, L.R.; Fong, P. Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: a computational and experimental study. Exp. Biol. Med. (Maywood). 2017, 242, 731–743.
[32]	Han, F.; Xing, R.H.; Chen, L.Q.; Chen, L.; Xiong, W.; Yang, M.; Zhao, Z.D. Research progress of anti-drug resistance in traditional Chinese medicine. China J. Chin. Mater. Med. 2016, 41, 813–817.